Immuno-oncology
Immuno-Oncology at the Forefront of Cancer Medicine
David Alvaro, Ph.D.
Pharma's Almanac
PAO-25-30-10Mar 02, 2025
Virotherapy
Oncolytic Virotherapy: Real Potential and Difficult Challenges
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-12-24-CL-1Dec 02, 2024
Advanced Therapies
A New Vision for Progressing Advanced Therapies
Nathaniel Youndt
ReciBioPharm
PAO-10-24-CL-13Oct 25, 2024
Oncolytic Viruses
Coverting Viruses into Therapeutic Tools
OncoMyx Therapeutics
PAO-04-22-R250-14Apr 12, 2022
Oncolytic Viruses
Best Practices For Oncolytic Virus Design, Development, and Manufacturing
Heidi Trusheim, Ph.D.; Trevor Broadt
IDT Biologika
PAO-02-022-CL-17Mar 09, 2022
CDMO Acquisition
Vibalogics Acquired by Top Global CDMO Recipharm AB
Vibalogics
PR-M02-22-18Feb 18, 2022
Oncolytic Virus
Specialized Know-How and Capacity to Support Demand for Oncolytic Viruses
Kai Lipinski, Ph.D.; Stefan Beyer, Ph.D.
Vibalogics
PAP-Q1-20-CL-032Mar 19, 2020